|1.||Cassuto, J: 2 articles (12/2003 - 12/2002)|
|2.||Yregård, L: 2 articles (12/2003 - 12/2002)|
|3.||Berg, A: 2 articles (05/2001 - 10/2000)|
|4.||Rubin, K: 2 articles (05/2001 - 10/2000)|
|5.||Reed, R K: 2 articles (05/2001 - 10/2000)|
|6.||Herrington, Margery K: 1 article (08/2010)|
|7.||Permert, Johan: 1 article (08/2010)|
|8.||Larsson, Jörgen: 1 article (08/2010)|
|9.||Wang, Feng: 1 article (08/2010)|
|10.||Siren, Pontus M A: 1 article (01/2010)|
03/07/1997 - "The putative neuropeptide Y antagonist, alpha-trinositol (10 microM), significantly attenuated the nerve injury-induced hyperalgesia. "
01/16/1995 - "Mechanical and thermal hyperalgesia were both relieved by alpha-trinositol (PP56), a non-competitive antagonist of the actions of neuropeptide Y. "
|2.||Brain Edema (Cerebral Edema)
01/01/1994 - "No significant reduction of brain swelling was found in animals with low-dose torasemide (8.51 +/- 0.63%) or low- (7.91 +/- 0.60) and high-dose PP56 (6.85 +/- 1.05%) as compared to the untreated controls. "
01/01/1994 - "The efficacy of torasemide, a novel chloride-channel blocker, and of PP56, an IP3 analogue, was currently examined in experimental brain edema. "
08/01/2003 - "We conclude that alpha-trinositol limits the increased vascular permeability and edema formation by preventing the decrease in P(if) as well as acting protective on the microvascular wall."
08/01/2003 - "The edema formation, and lowering of P(if) during I/R injury was significantly lowered and nearly totally abolished in the animals treated with alpha-trinositol 30 min before reperfusion. "
07/09/1999 - "Alpha-trinositol attenuates edema formation and capillary albumin extravasation and lowering of interstitial fluid pressure (Pif) in several acute inflammatory reactions in rat skin or trachea. "
01/01/1998 - "alpha-Trinositol given after a 90 degrees C scald blunted edema formation at the site of scald, likely through reduced transmembrane fluid flux."
01/01/1998 - "Alpha-trinositol reduces edema formation at the site of scald injury."
08/01/2010 - "During the 12 weeks, seven tumor-cell recipients were treated with PP56 by daily injection (PPT mice). "
08/01/2009 - "To determine the effectiveness of the polyanionic, metal binding agent D-myo-inositol-1,2,6-triphosphate (alpha trinositol, AT), and its hexanoyl ester (HAT), in tissue wasting in cancer cachexia. "
08/01/2009 - "Attenuation of skeletal muscle atrophy in cancer cachexia by D-myo-inositol 1,2,6-triphosphate."
08/01/2010 - "In this study, we investigated whether the anti-inflammatory drug PP56 (alpha-trinositol) may improve cancer-induced metabolic disorders. "
12/01/2002 - "The effects of alpha-Trinositol on inflammation and fluid losses in the obstructed small intestine are examined. "
11/01/1994 - "The anti-inflammatory drug alpha-trinositol (1,2,6-D-myo-inositol trisphosphate) stabilizes Pif in acute inflammation. "
01/01/1990 - "The anti-inflammatory effects of D-myo-inositol-1.2.6-trisphosphate (PP56) on animal models of inflammation."
09/01/1997 - "Effects of alpha-trinositol on systemic inflammation and renal function in ovine bacterial sepsis."
05/01/2001 - "The experiments with alpha-trinositol and platelet-derived growth factor-BB suggest that the connective tissue can serve as a novel target for pharmacologic intervention in inflammation."
|3.||Chloride Channels (Chloride Channel)
|5.||Edetic Acid (EDTA)
|6.||ethylenediamine (ethylenediamine dihydroiodide)
|9.||Fatty Acid Desaturases
|10.||Glutamic Acid (Glutamate)
|1.||Vagus Nerve Stimulation